María Ángeles González-Nicolás, Cristian González-Guerrero, Verónica Astrid Pérez-Fernández, Alberto Lázaro.
Clinical Kidney Journal, Volume 13, Issue 5, October 2020, Pages 903–905.
- DOI: 10.1093/ckj/sfaa193
Based on the preclinical evidence of kidney and lung protection in the context of endotoxemia as presented in this letter.
We propose that cilastatin should be studied in clinical trials as a potential therapy for COVID-19.
The current understanding of the drug mechanism of action suggests that it may both decrease viral entry and consequently viral replication, and additionally may protect from the deleterious consequences of the cytokine storm observed in severe COVID-19.
Indeed, a clinical trial of the Fas ligand trap asunercept is planned (https://www.pharmiweb.com/press-release/2020-07-28/apogenix-to-start-european-clinical-phase-ii-trial-with-asunercept-in-covid-19-patients).
